title: Development and preliminary evaluation of a multivariate index assay for ovarian cancer.
abstract: BACKGROUND
  Most women with a clinical presentation consistent with ovarian cancer have benign conditions. Therefore methods to distinguish women with ovarian cancer from those with benign conditions would be beneficial. We describe the development and preliminary evaluation of a serum-based multivariate assay for ovarian cancer. This hypothesis-driven study examined whether an informative pattern could be detected in stage I disease that persists through later stages.
  
  
  RESULTS
  Sera, collected under uniform protocols from multiple institutions, representing 176 cases and 187 controls from women presenting for surgery were examined using high-throughput, multiplexed immunoassays. All stages and common subtypes of epithelial ovarian cancer, and the most common benign ovarian conditions were represented. A panel of 104 antigens, 44 autoimmune and 56 infectious disease markers were assayed and informative combinations identified. Using a training set of 91 stage I data sets, representing 61 individual samples, and an equivalent number of controls, an 11-analyte profile, composed of CA-125, CA 19-9, EGF-R, C-reactive protein, myoglobin, apolipoprotein A1, apolipoprotein CIII, MIP-1alpha, IL-6, IL-18 and tenascin C was identified and appears informative for all stages and common subtypes of ovarian cancer. Using a testing set of 245 samples, approximately twice the size of the model building set, the classifier had 91.3% sensitivity and 88.5% specificity. While these preliminary results are promising, further refinement and extensive validation of the classifier in a clinical trial is necessary to determine if the test has clinical value.
  
  
  CONCLUSIONS
  We describe a blood-based assay using 11 analytes that can distinguish women with ovarian cancer from those with benign conditions. Preliminary evaluation of the classifier suggests it has the potential to offer approximately 90% sensitivity and 90% specificity. While promising, the performance needs to be assessed in a blinded clinical validation study.
authors.affiliation: Correlogic Systems, Inc., Rockville, Maryland, United States of America.
authors.forename: Suraj D
authors.initials: SD
authors.lastname: Amonkar
authors.forename: Greg P
authors.initials: GP
authors.lastname: Bertenshaw
authors.forename: Tzong-Hao
authors.initials: TH
authors.lastname: Chen
authors.forename: Katharine J
authors.initials: KJ
authors.lastname: Bergstrom
authors.forename: Jinghua
authors.initials: J
authors.lastname: Zhao
authors.forename: Partha
authors.initials: P
authors.lastname: Seshaiah
authors.forename: Ping
authors.initials: P
authors.lastname: Yip
authors.forename: Brian C
authors.initials: BC
authors.lastname: Mansfield
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood*; D001185:Artificial Intelligence; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007118:Immunoassay; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D012680:Sensitivity and Specificity; D012698:Serologic Tests
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor